PORTFOLIO NEWS ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101 December 21, 2020 Read More » NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors December 9, 2020 Read More » Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing December 8, 2020 Read More » Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition December 7, 2020 Read More » Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T December 7, 2020 Read More » Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting December 6, 2020 Read More » ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares November 17, 2020 Read More » RAPT Therapeutics Reports Positive Initial Data From Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications November 16, 2020 Read More » RAPT Therapeutics Reports Third Quarter 2020 Financial Results November 16, 2020 Read More » NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy November 13, 2020 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101 December 21, 2020 Read More »
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors December 9, 2020 Read More »
Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing December 8, 2020 Read More »
Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition December 7, 2020 Read More »
Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T December 7, 2020 Read More »
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting December 6, 2020 Read More »
ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares November 17, 2020 Read More »
RAPT Therapeutics Reports Positive Initial Data From Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications November 16, 2020 Read More »
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy November 13, 2020 Read More »
